Category: M2BIO

CAPE TOWN, South Africa, July 02, 2019 (GLOBE NEWSWIRE) — via NetworkWire — Wuhan General Group (China), Inc. (OTC PINK: WUHN) (the “Company” and “Wuhan”), is pleased to share the following statements and coming milestones:

Statements

• The company would like to clarify for all past, current and potential future shareholders that Wuhan General Group is a US-registered corporation and has no dealings with any Chinese parties as it relates to its ongoing business activities. To remove any possible confusion with its current name and to better reflect the nature of the business, the Company has retained the services of a law firm to specifically take all necessary steps to file a name change with FINRA. Once approved, the company will issue a press release to inform shareholders.
• The Company is currently investigating all options regarding an up-listing and becoming a fully reporting issuer. Wuhan will share more information as it becomes available.
• The Company last month closed on the purchase of 49% of Biodelta Nutraceuticals, Ltd. (“Biodelta”) assets at a cost price of $USD1.567 Million financed by private funding. No shares have been issued for this transaction. Biodelta Nutraceuticals, Ltd. assets which include the land, buildings, and the infrastructure as well as the specialized greenhouse and drying ovens. These assets will be part of our new operational facility located near Cape Town, South Africa. This transaction enables Wuhan to produce 36,000 kg of Cannabis in phase one (300k sq. ft) which is ready to grow, and 175,000 kg (1.3M sq. ft) in phase 2, planned for later this year. The acquisition will allow Wuhan to produce a very high-end organic pharmaceutical grade CBD, eliminating the risk of shortage as well as being cost-efficient.

Milestones

• Biodelta Nutraceuticals has been contracted to support the Company’s wholly-owned subsidiary, MJ MedTech Inc. to develop, brand, market and commercialize its internationally trademarked Dr. AnnaRx™. The Company is planning to have its first Dr. AnnaRx™ line of CBD based products in stores this month and expand across South Africa in more than 1,000 pharmacies in the following weeks.

  List of products this month:

1. Dr. AnnaRx exclusive line of CBD infused beauty and health products: Day Cream, Night Cream, Serum, Shampoo, Conditioner, UV Sun Protector.
2. Medspresso™, an exclusive line of CBD infused espresso and coffee in capsule format. The flavors offered are Tanzanian Peaberry, light, medium and dark roast, and decaf coffee.

• The Company has retained the services of a law firm to work on the cancellation of 19,844,398 shares of WUHN Common Stock held by Fame Good International Limited previously issued under past management. Wuhan strongly believes that the shares were issued inappropriately and will be canceled and returned to the treasury. After cancellation, the outstanding shares count would be 22.4 million shares. A 47% reduction of the current outstanding shares counts of 42.2 million shares. Another positive step in enhancing shareholder value.
• The Company is delighted to witness US cities decriminalizing mushrooms containing the psychedelic psilocybin, also known as “magic mushrooms“. Wuhan anticipates this trend to continue not only in the US but globally. M2BIO was specifically set up to be a leader in the field of research and commercialization of medicines derived from mushrooms containing psilocybin. Wuhan believes the mushroom sector as it develops will have as much if not more potential market size than the cannabis sector. More information regarding international joint venture and partnership will be available once finalized.
• Wuhan, Biodelta, and ARC are currently working out the details for a comprehensive memorandum of understanding (MOU) as it relates to cannabis and mushrooms. The Agricultural Research Council (ARC) is the premier science institution in the southern hemisphere that conducts research with partners, develops human capital and fosters innovation to support and develop the agricultural sector.  Much more on this very powerful partnership will be released via a Company press release.

About Biodelta Nutraceuticals

Biodelta Nutraceuticals (ISO 22000 and organic certified) is a Cape Town-based manufacturer and merchandiser of premium health products to all pharmacy & health shop chains across South Africa. For the past 12 years, Biodelta has developed, designed and produced more than 1,000 products for these customers and is now strategically positioned to launch CBD products through these channels. In addition, Biodelta has license applications in the progress for growing, extracting and product development as well as dossiers for various CBD based products.

For further information contact:

Website: https://biodelta.net/

Public Relations E-mail: info@biodelta.net

About Wuhan General Group (China), Inc.

Wuhan General Group (China), Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under the Dr. AnnaRx brand. In addition, its new division, M2BIO aims to explore and develop additional indications for psilocybin new therapies that will help patients who suffer from mental illness. Our mission is to advance botanical-based medicine to the forefront by deploying best practice science and medicine, clinical research and emerging technologies.

For further information contact:
Publicly traded company (OTC Pink: WUHN)
Website: www.wuhn.org
Public Relations E-mail: info@wuhn.org

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

Source: Wuhan General Group (China), Inc.

 

BARCELONA, Spain, May 17, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE — Wuhan General Group (China), Inc. (OTC: WUHN) (the “Company” and “Wuhan”), is thrilled to announce the signing of a very remarkable Letter of Intent (LOI) with Biodelta.

The LOI calls for the purchase by Wuhan of 49% of the land, buildings, and infrastructure including the specialized greenhouse and drying ovens. A full agreement between the parties is expected to be reached in 45 days. More details will be made available after the signing of the full agreement. The assets to be acquired include but are not limited to:

• 1.3 million square feet of cultivation space of which 300,000 square feet is turnkey and ready to go as necessary permits are approved and issued. The additional 1,000,000 sq ft. will be built out and readied for early 2021.
• Specialized processing factory ISO 22000
• 8 Industrial GMP compliant dryers
• Water rights

“When we visited Biodelta in South Africa last month and saw first-hand the opportunity and possibilities we knew this was a deal that had to be made. This puts Wuhan on the global stage immediately in terms of sheer size and cannabis production capacity. Preliminary forecasts would see Wuhan produce 36,000 kg in phase one (300k sq. ft), and 175,000 kg (1.3M sq. ft) at full capacity,” said MJ Medtech CEO Jeff Robinson.

Leon Giese, Biodelta CEO added: “Biodelta has been at the forefront of South Africa’s algal biotech industry since 2004 through its growing and commercialization of Spirulina products into the pharma market in Europe, Asia, and the Americas. Biodelta recognizes the massive opportunity to exploit the growing worldwide demand for South African medicinal herbs. Biodelta has the facilities in place currently to grow under 300,000 square feet of specialized greenhouse and to evaporatively dry, process, formulate, brand and distribute a range of value-added CBD products into its retail pharmacy market throughout Southern Africa as well as its customers worldwide.”

About Biodelta Nutraceuticals

Biodelta Nutraceuticals (ISO 22000 and organic certified) is a Cape Town-based manufacturer and merchandiser of premium health products to all pharmacy & health shop chains across South Africa. For the past 12 years, Biodelta has developed, designed and produced more than 1,000 products for these customers and is now strategically positioned to launch CBD products through these channels. In addition, Biodelta has license applications in process for growing, extracting and product development as well as dossiers for various CBD based products.

For further information contact:

Website: https://biodelta.net/

Public Relations E-mail: info@biodelta.net

About Wuhan General Group (China), Inc.

Wuhan General Group (China), Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under the Dr. AnnaRx brand. In addition, its new division, M2BIO aims to explore and develop additional indications for psilocybin new therapies that will help patients who suffer from mental illness. Our mission is to advance botanical-based medicine to the forefront by deploying best practice science and medicine, clinical research and emerging technologies.

For further information contact:

Publicly traded Company (OTC: WUHN)

Website: www.wuhn.org

Public Relations E-mail: info@wuhn.org

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

Source: Wuhan General Group (China), Inc.

BARCELONA, Spain, May 09, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE — Wuhan General Group (China), Inc. (OTC PINK: WUHN) (the “Company” and “Wuhan”), and M2BIO is delighted to share the voting results of Initiative 301 held in Denver last night. Denver will become the first US city to effectively decriminalize mushrooms containing the psychedelic psilocybin, also known as “magic mushrooms.”

“This is a big step forward for medicine and research into medicinal mushrooms. No different than how marijuana laws loosened up over time, the same will happen with mushrooms creating huge opportunities,” said Dr. Anna, Medical Doctor, CMO of Wuhan.

This type of pioneering vote isn’t new for Denver or Colorado as a whole. In 2012, Colorado’s and Washington’s state became the first two states to legalize marijuana for recreational use. Oregon and California, are considering measures to change their laws regarding psilocybin as well.

“The Denver vote and results are truly groundbreaking news for Wuhan and M2BIO. We are really looking forward to sharing very soon in details our medicinal mushroom roadmap in South Africa with our partner BioDelta,” said Jeff Robinson, MJ MedTech CEO.

Leon Giese, Biodelta CEO added: “BioDelta has deep experience in producing medicinal plants under ISO 9001 certification and we are eager to be working with Wuhan to grow and commercialize medicinal mushrooms into our existing supply chain.”

About M2BIO

M2BIO aims to develop new therapies that will help patients who suffer from mental illness and ease the burden on healthcare systems globally. This division will be exploring additional indications for psilocybin, with the goal of bringing new therapies to market.

Psilocybin mushrooms (AKA magic mushrooms, or shrooms) is the name given to fungi that contain psilocybin, a naturally occurring psychedelic compound. Psilocybin mushrooms have been used in therapeutic settings to treat a wide variety of ailments and disorders including cluster headaches, obsessive-compulsive disorders, anxiety, depression, and addiction.

About Wuhan General Group (China), Inc.

Wuhan General Group (China), Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that research, develops and commercializes a range of CBD-based products under the Dr. AnnaRx brand. In addition, its new division, M2BIO aims to explore and develop additional indications for psilocybin new therapies that will help patients who suffer from mental illness. Our mission is to advance botanical-based medicine to the forefront by deploying best practice science and medicine, clinical research and emerging technologies.

For further information contact:

Publicly traded company (OTC Pink: WUHN)

Website: www.wuhn.org

Public Relations E-mail: info@wuhn.org

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

Source: Wuhan General Group (China), Inc.

BARCELONA, Spain, April 05, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE — Wuhan General Group (China), Inc. (OTC PINK: WUHN) (the “Company” and “Wuhan”), announced today that its subsidiary MJ MedTech, Inc. (MJ MedTech) has created a new division dedicated to exploring opportunities in the psychedelic medicine space. The new division, M2BIO will be headed up by Wuhan’s CMO, Dr. Anna Morera Lorelta.

According to Dr. Anna, psychedelic medicine is experiencing a remarkable revival in the wake of recent research studies and positive findings from great institutions, such as Johns Hopkins. Researchers are having great success in treating depression, post-traumatic stress disorder (PTSD), anxiety and certain addictions with Psilocybin, the active naturally occurring psychedelic pro-drug compound produced by specific mushrooms, known as “magic mushrooms”.

Psilocybin therapy is a medical practice in which psilocybin, a psychoactive medicine, is administered to a patient during a session supported by a therapist. A psychoactive medicine is one that affects brain function and results in a change in cognition, perception or behavior.

”Psilocybin has become a very promising candidate for future treatments for anxiety and depression because it appears to disrupt the sorts of engrained brain activity patterns that are the hallmark of those diseases.” Said Dr. Anna.

“Just like it took time for the regulators to get behind marijuana, we believe the same will happen with “magic mushrooms” in due course. We want to be far ahead of the curve and become pioneers in the market, collaborating with legislative bodies to help find better and healthier solutions,” added MJ MedTech CEO, Jeff Robinson.

The new division, M2BIO aims to develop new therapies that will help patients who suffer from mental illness and ease the burden on healthcare systems globally. This division will be exploring additional indications for psilocybin, with the goal of bringing new therapies to market in the years to come.

About Wuhan General Group (China), Inc.

Wuhan General Group (China), Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that owns, develops and commercializes a range of CBD-based products. At Wuhan, our mission is to advance CBD-based medicine to the forefront by deploying best practice science and medicine, clinical research and emerging technologies.

For further information contact:

Publicly traded company (OTC Pink: WUHN)

Website: www.wuhn.org

Public Relations E-mail: info@wuhn.org

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

Source: Wuhan General Group (China), Inc.

BARCELONA, Spain, March 28, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE —  Wuhan General Group (China), Inc. (OTC: WUHN) (the “Company” and “Wuhan”), announced today that its subsidiary MJ MedTech, Inc. (MJ MedTech) has commenced formulations and prototyping for the Dr. AnnaRx line of hemp and CBD based products.

The products listed below are being developed in Phase 1 and readied for sale for Q2 2019 onward. These products come under the Cosmetics and Food segments.

Cosmetic

• Day Cream
• Night Cream
• Facial Cleanser
• Facial Exfoliator
• Anti-Aging
• Shampoo & Conditioner
• SPF 50+ Sunblock

Food

• CBD Olive Oil
• CBD Salad Dressing
• Infused Coffee
• Infused Tea
• Infused Honey
• CBD Chocolate

In Phase 2 and 3, the range of products will fall under the Topicals and CAMS (Complementary and Alternative Medicines) segment, respectively. The Company is expected to launch its range of Phase 2 and 3 products to the market in Q4 2019 onward.

Topicals

• CBD Balms for pain and inflammation
• CBD Ointments for joint care
• CBD Creams for mind and mood
• Soft gels

CAMS

• Capsules
• Suppositories
• CBD Extracts
• Antioxidants
• Immune Booster
• Multivitamins

More highlights:

• The Company forecasts revenues for Q2, Q3 and Q4 2019 of the amount of $585,000, $2,047,500 and $5,265,000, respectively.
• Wuhan management executives will be visiting South Africa in April to ensure operational performance and conduct product testing by Wuhan’s Chief Medical Officer against our quality standards.
• MJ Medtech will officially relocate the head office to Barcelona, Spain in anticipation of the European launch in 2020 where the Dr. AnnaRx line of hemp and CBD-based products will be sold as well as across South Africa and surrounding countries in more than 1,000 pharmacies in 2019.

Wuhan management believes in the transition to the cannabis industry as a strategic move that will ensure future company growth and shareholder value. We are eager to share our vision and success.

About Wuhan General Group (China), Inc.

Wuhan General Group (China), Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that owns, develops and commercializes a range of CBD-based products. At Wuhan, our mission is to advance CBD-based medicine to the forefront by deploying best practice science and medicine, clinical research and emerging technologies.

For further information contact:

Publicly traded company (OTC Pink: WUHN)

Website: www.wuhn.org

Public Relations E-mail: info@wuhn.org

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

Source: Wuhan General Group (China), Inc.

LOS ANGELES, Jan. 30, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE — Wuhan General Group (China), Inc. (USOTC: WUHN) (the “Company” and “Wuhan”), announced today that its wholly-owned subsidiary MJ MedTech, Inc. (MJ MedTech) and Biodelta Nutraceuticals, Ltd. (Biodelta) have entered into a joint venture to develop, brand, market and commercialize the internationally trademarked Dr. AnnaRx.

The joint venture calls for an initial pilot whereby the Dr. AnnaRx line of CBD based products will be sold (as regulations allow) across South Africa in more than 1,000 pharmacies. The data Biodelta collects on the pilot will enable them to ensure the Dr. AnnaRx brand will deliver the highest possible ROI when introduced internationally.

This partnership marks a very strong start to 2019 for MJ MedTech as the Company expects to have product on the shelves by Q2/3 of 2019.

Dr. Anna Leralta, CMO of Wuhan, commented, “I’m thrilled to be working with the very strong scientific team at Biodelta. They have proven for many years their outstanding track record and expertise in the field of science-backed nutraceuticals. They are an ideal partner to help support our vision of developing effective CBD products backed by sound science.”

Under the terms of the Agreement, Biodelta will exclusively develop, distribute and merchandise all products sold under the Dr. AnnaRx brand in South Africa and 8 additional African countries across the African continent.

Leon Giese, CEO of Biodelta, added, “There is a growing demand for CBD products in the South African market. Retailers and consumers want a brand they can trust, and we believe Dr. AnnaRx is a perfect fit.”

About Biodelta Nutraceuticals

Biodelta Nutraceuticals (ISO 22000 and organic certified) is a Cape Town-based manufacturer and merchandiser of premium health products to all pharmacy & health shop chains across South Africa. For the past 12 years, Biodelta has developed, designed and produced more than 1,000 products for these customers and is now strategically positioned to launch CBD products through these channels. In addition, Biodelta has license applications in process for growing, extracting and product development as well as dossiers for various CBD based products.

For further information contact:

Website: https://biodelta.net/

Public Relations E-mail: info@biodelta.net

About Wuhan General Group (China), Inc.

Wuhan General Group (China), Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that owns, develops and commercializes a range of CBD-based products. At Wuhan, our mission is to advance CBD-based medicine to the forefront by deploying best practice science and medicine, clinical research and emerging technologies.

For further information contact:

Publicly traded company (USOTC: WUHN)

Website: www.wuhn.org

Public Relations E-mail: info@wuhn.org

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

Source: Wuhan General Group (China), Inc.

MONTREAL, Sept. 14, 2018 (GLOBE NEWSWIRE) — via OTC PR WIRE — Wuhan General Group (China), Inc. (OTC PINK: WUHN) (the “Company”), a Nevada investment company focused on the industrial technology and other emerging market space, is pleased to announce its completion of the first stage in the reorganization of the Company’s share structure. This restructuring, consistent with the Company’s strategic growth plans, will serve to increase shareholder value and enhance the Company’s growth potential.

The company has reduced its outstanding common shares from 100 million to approx. 39.7 million. All canceled shares have been returned to the company treasury to be used in future acquisitions as well as to raise funds by means of private placements for present and future projects. This action will allow the Company to increase its cash flow without increasing the authorized number of shares.

“We are excited about achieving this milestone on our roadmap planned for 2018 and next year,” said CEO, Ramy Kamaneh. “As we continue evaluating our Company operations, we will continue building a strong foundation to create a successful company that benefits all shareholders. We are excited about achieving this goal and are in the process of doing so with what is to come.”

About Wuhan General Group (China) Inc

Wuhan General Group (China), Inc., based in Nevada, is an investment company focused in the areas of Cryptocurrency mining operations and infrastructure. In addition to its strong commitment in facilitating the development and adoption of cryptocurrency mining operations, Wuhan continues to pursue distinct investment decisions based on emerging markets that reflect the highest business, technical, and legal standards.

Wuhan General Group (China), Inc.
Publicly traded company (OTC Pink:WUHN)
Website: www.wuhn.org

For further information contact:
Public Relations
E-mail: info@wuhn.org

Forward-Looking Statements

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

Source: Wuhan General Group (China), Inc

MONTREAL, Sept. 11, 2018 (GLOBE NEWSWIRE) — via OTC PR WIRE — Wuhan General Group (China), Inc. (OTC PINK: WUHN) (the “Company”), a Nevada investment company focused in cryptocurrency mining operations announced today that it’s currently negotiating a redesign of a US Defense Department data center to transform it into a Cryptocurrency mining facility. The facility will meet security and power requirements when mining cryptocurrency. It will also provide the Company with an opportunity to set new standards in cryptocurrency mining safety, stability, and security measures.

This new facility will launch at an optimal time in the market to strengthen the Company’s cryptocurrency mining division for highly scalable and flexible mining operations across all major cryptocurrencies. The Company benefits from low-cost North American power, a cool climate, and high-speed Internet, which is critical to mining success, placing it in a competitive position to maximize profitability. Ultimately, the project comes at a time that will serve in the Company’s and shareholders’ best interests.

The 55,0000 sq. ft facility has over 3MW of power ready to accommodate up to 1300 mining machines for Bitcoin, Zcash, and others with an additional 12,000 to be deployed upon successful completion of its upgrade to a 30MW facility in 2019. Once the negotiation is finalized, the first order of rigs from Asicminer is expected to arrive in late October and more in the coming months. The Company estimates this operation to bring monthly revenue in excess of $3.5M based on current cryptocurrency market prices for the initial 1300 mining machines in operation. More information will be shared regarding the progress of the project when available.

Ramy Kamaneh, CEO said: “We had planned to build this operation three months ago, but with the bearish cryptocurrency market, we took a step back to reassess our strategy. The decision to wait for market stability was a good one, especially considering many cryptocurrency machines are no longer profitable in the current market. We acted in the best interests of the Company and its shareholders and firmly believe that the market has bottomed and a bullish market is starting again.”

In addition to providing optimal cryptocurrency mining performance, the facility will adhere to strict safety and security standards. As a leader in streamlined solutions that respond to the impacts of the tech industry, the Company believes that this project will increase in value and also create opportunities for innovation within the sector.

About Wuhan General Group (china) Inc

Wuhan General Group (China), Inc., based in Nevada is an investment company focused in the areas of Cryptocurrency mining operations and infrastructure. In addition to its strong commitment in facilitating the development and adoption of cryptocurrency mining operations, Wuhan continues to pursue distinct investment decisions based on emerging markets that reflect the highest business, technical, and legal standards.

Wuhan General Group (China), Inc.
Publicly traded company (OTC Pink:WUHN)
Website www.wuhn.org

For further information contact:
Public Relations
E-mail: info@wuhn.org

Forward-Looking Statements

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

Source: Wuhan General Group (China), Inc

Once finalized, shareholders of WUHN before the cut-off date will receive shares of SDT, therefore benefiting from all four existing subsidiaries under two fully reporting parent companies.

After the spin-off, Wuhan General Group, Inc. will focus its operation on large-scale mining cryptocurrency farms and explore other potential avenues and acquisitions to bring additional sources of income and assets to the company.

SDT, the private Canadian company, will become a fully traded public company on both the US and Canadian market exchange and will continue its operations through its subsidiaries including SDIT, SDET, and SDMT.

MONTREAL, Sept. 05, 2018 (GLOBE NEWSWIRE) — via OTC PR WIRE — Wuhan General Group (China), Inc. (OTC PINK: WUHN) (the “Company”), a Nevada investment company focused on the industrial technology market space, announced its plan to pursue a spin-off of the Company’s Canadian tech-related business, Strategic Development of Technology (SDT), Inc. to Company shareholders. The separation is a strategic move by the Company to benefit its shareholders with the enhanced growth potential of two fully reporting parent companies that span multiple fast-developing industries. The transaction is intended to take the form of a tax-free distribution to Wuhan shareholders, who are eligible to receive SDT common stock shares. The distribution ratio and Record Date will be announced at a later time.

With SDT as a standalone public company, the spin-off will ensure that Wuhan shareholders will continue to benefit from SDT subsidiaries. Following the transaction, each parent company will have distinct corporate strategies and capital allocation priorities:

1. Wuhan’s portfolio of businesses will be comprised primarily of industry-leading blockchain technology development (SDBT). By isolating its cryptocurrency profile, the Company is expected to generate stable growth opportunities and focus its strategy to acquire and generate business in new industries.
2. The spin-off of the private company Strategic Development of Technology (SDT) into a public company will be focused on the development of batteries (SDET), electric equipment (SDMT), and Intelligence (SDIT) technology. SDT’s subsidiaries have leading positions in industrial mining and energy markets throughout North America. The spin-off transaction will position these three subsidiaries to drive industry growth and initiatives in creating sustainable solutions for these markets.

Benefits of the Spin-off Transaction:

Enhances overall growth potential through two focused companies

Wuhan believes that both the growth potential and overall valuation of its businesses will be enhanced as a result of separating its current portfolio into two separate companies. The Nevada based Investment company and the Canadian Technology Development company will each be more focused and competitive as leading standalone companies in their respective industries.

Expands trading opportunities in the US and Canada

The spin-off of SDT will allow a compelling opportunity by trading on both the OTCQB and CSE markets.

Enables each company to advance differentiated investments

Wuhan believes that this transaction will yield new opportunities to generate business and provide value through new market opportunities. This enables investors to clearly evaluate the inherent value of each company’s portfolio of assets and invest accordingly.

Maintains benefits of SDT’s industrial technology development structure

As a fully reporting public company, SDT can continue to improve upon its unparalleled contributions to the sustainable industrial technology sector.

Next Steps:

The private company, SDT will undergo an audit during the month of September and then file its initial registration statement with the Securities and Exchange Commission to be a fully reporting company. The Company plans on listing SDT on the OTC Markets OTCQB marketplace first, then on the CSE.

Once the separation is complete, Wuhan General Group (China), Inc. will file its three years of audited financials to become a fully reporting company as well as uplisting to OTCQB; the name and ticker change will follow. The Company will continue to provide shareholders with transaction details as they arise. A new corporate website for Wuhan and SDT will go live prior to the Record Date, which will be announced at a later time.

About Wuhan General Group (China) Inc.

Wuhan General Group (China), Inc., based in Nevada, is an investment company focused in the areas of Cryptocurrency mining operations and infrastructure. In addition to its strong commitment to facilitate the development and adoption of cryptocurrency mining operations, Wuhan continues to pursue distinct investment decisions based on emerging markets that reflect the highest business, technical, and legal standards.

About SDT Inc.

SDT is a Montreal-based Canadian technology holding company whose primary business operations are conducted through its operating subsidiaries SDMT, SDET, and SDIT. The subsidiaries are engaged in the research, development, and manufacturing of industrial battery technologies and electric Material Handling Equipment (eMHE) to assist the mining, construction, and agricultural industries in eliminating greenhouse gas (GHG) emissions by moving from diesel power to a battery-powered energy source.

SDT subsidiaries are also exploring the research and application of artificial intelligence and blockchain technologies to the mining, agriculture and construction industries.

Wuhan General Group (China), Inc.
Publicly traded company (OTC Pink:WUHN)
Website: www.wuhn.org

Strategic Development of Technology, Inc.
Private company
Website: www.sdtholdings.com

For further information contact:
Public Relations
Phone: (514) 928-7368
E-mail: info@wuhn.org

Forward-Looking Statements

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

Source: Wuhan General Group (China), Inc.

MONTREAL, Sept. 04, 2018 (GLOBE NEWSWIRE) — via OTC PR WIRE — Wuhan General Group (China), Inc. (OTC PINK: WUHN) (the “Company”), a Nevada investment company focused on the industrial technology market space, announced today that its Board of Directors has unanimously approved a plan to pursue a spin-off of the Company’s Canadian tech related business, Strategic Development of Technology (SDT), Inc, to Company shareholders. The separation is planned as a tax-free spin-off transaction to the Company’s shareholders and is expected to be completed in the fourth quarter of 2018.

The transaction is expected to result in two separate public companies that will benefit from leading positions in their respective industries. As of the Record Date (cut-off date), the Company shareholders will be eligible to receive SDT common stock shares. The transaction is intended to take the form of a tax-free distribution to Company shareholders. The expected stock distribution ratio will be confirmed in the comings weeks.

Ramy Kamaneh, CEO said: “We believe that establishing SDT as a stand-alone, fully reporting public company will allow for us to align more closely with our strategic initiatives. It will also give the investment community clearer insight into the potential value our businesses can continue to create. As a Canadian company, this is a compelling opportunity to reach investors in the U.S. and in Canada by trading on both the OTCQB and CSE stock exchange markets.”

The Company anticipates that the spin-off will enhance the growth potential and overall valuation of its businesses as a result of creating two separate companies specialized in fast-growing industries. With the added advantage of access to both Canada and U.S. market, the Company is confident it will better serve shareholders. It will also allow each company to be more focused and competitive in their respective industries. This announcement will also serve to enable SDT to execute even better on their strategy and drive their vision of a sustainable and equitable industrial technology market. Once the separation completed, Wuhan General Group (China), Inc will file its 3 years of audited financials to become a fully reporting company as well as up listing to OTCQB, and apply for name and ticker symbol change.

Additional Details

The Record date and completion of the transaction is subject to certain usual conditions, including SEC, Legal and shareholder approvals. The Company currently anticipates the Distribution Date to be in December 2018. Dates are subject to change. The Company will release information in the coming weeks with definitive dates and further information.

About Wuhan General Group (china), Inc.

Wuhan General Group (China), Inc. is a Nevada based investment company focused in the areas of Cryptocurrency mining operations, battery & electric material handling equipment manufacturing, services in artificial intelligence, as well as Internet of Things hardware. In addition to this, they are also dedicated to working in the application of blockchain technologies to mining, agriculture and construction industries.

About Strategic Development of Technology (SDT), Inc.

SDT, Inc. is a Montreal-Based Canadian corporation engaged in the research, development and manufacturing of industrial battery technologies and electric Material handling equipment (eMHE) to assist the mining, construction and agricultural industries in eliminating greenhouse gas (GHG) emissions by moving from diesel power to a battery-powered energy source. SDT’s deep understanding of battery chemistry and the in-field operations for industries such as the underground mining industry, gives it a competitive advantage to become a leader in the development of this space as well as in assisting these industries in their adoption to battery powered material handling equipment.

By complementing its industrial batteries and eMHE with predictive maintenance using artificial intelligence and hardware (Internet of things), SDT can effectively manage and coordinate a full-scale battery-powered operation and charging infrastructure 24-7 at some of the most remote locations in the world.

SDT is also building, through its subsidiary, a cryptocurrency mining operation as well as exploring the research and application of blockchain technologies to the mining, agriculture and construction industries.

Wuhan General Group (China), Inc.

Publicly traded company (OTC Pink:WUHN)
Website:www.sdtholdings.com

For further information contact:

Public Relations
Phone: (514) 928-7368
E-mail:info@sdtholdings.com

Forward-Looking Statements

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

Source: Wuhan General Group (China), Inc.